Founded in 2011 and listed on the Hong Kong Stock Exchange in 2018, Innovent has a fully-integrated platform for research, development, manufacturing, and commercialization. They have a pipeline of 23 assets in various therapeutic areas, including cancer, metabolic, and autoimmune diseases. Innovent has successfully launched four products in China and has several assets in advanced clinical trials. They have established global-standard biopharmaceutical production facilities and have formed strategic partnerships with international pharmaceutical companies. Innovent is funded by Fidelity, Lilly Ventures, and Suzhou bioBay, and their team has extensive experience in biologics development and manufacturing.